Back to search results
NCT06474091

Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)

Enrolling by Invitation
Not specifiedAges 18+Observational
Mayo Clinic
~100 participants
Updated 2026-03-16 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Associate of PUMA levels with short term progression
Measured over Up to 5 years
+1 more outcome measured

Conditions

Cholangiocarcinoma

Explore related trials

Cholangiocarcinoma

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Nguyen H. Tran, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient has a suspected or clinical diagnosis of cholangiocarcinoma and under evaluation for surgical intervention with intent to cure
Age ≥ 18 years

Exclusion

Patient has metastatic disease involving other organs (excluding lymph node)
Patent has known primary cancer outside of the bile ducts within the last 3 years prior to blood collection (not including basal cell or squamous cell skin cancers, indolent cancer not requiring treatment within 3 years i.e. kidney, prostate or thyroid being observed)
Patient has had surgery to remove current target pathology completely or partially
Patient has undergone any prior radiation therapy to target lesion prior to blood collection
Patient has received chemotherapy class drugs in the 3 years prior to blood collection
Patient has had any transplants prior to blood collection
Current target pathology is a recurrence

What this trial measures

  • Associate of PUMA levels with short term progressionUp to 5 years

    Proteins, mUtations, Methylated DNA, and Aneuploidy (PUMA) markers will be assessed pre- and post-treatment and will be associated with treatment response to therapy (short term progression; time to cholangiocarcinoma recurrence).

  • Associate of PUMA levels with progression free survivalUp to 5 years

    Pre-surgical and post-surgical PUMA levels will be associated with progression free survival (time to death from cholangiocarcinoma).